Alector (ALEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually for shareholder participation.
Proxy materials, including the annual report and proxy statement, are available online or by request.
Voting matters and shareholder proposals
Election of three directors: Elizabeth Garofalo, M.D., Errol De Souza, Ph.D., and Kristine Yaffe, M.D.
Ratification of Ernst & Young, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Board recommends voting "FOR ALL NOMINEES" and "FOR" both other proposals.
Board of directors and corporate governance
Board nominees include individuals with medical and scientific backgrounds.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alector
- Pivotal FTD-GRN phase III data and AL101 phase II enrollment expected in 2025, backed by strong liquidity.ALEC
Q4 20249 Jul 2026 - ABC platform achieves high-efficiency brain delivery for diverse therapies, advancing CNS drug innovation.ALEC
Status Update9 Jul 2026 - CB-010 and CB-011 prioritized for scalable, durable cell therapies, with cash runway into 2027.ALEC
BofA Securities 2025 Healthcare Conference9 Jul 2026 - Strong cash and late-stage pipeline position support major data readouts and potential AbbVie milestone.ALEC
Q2 20248 Jul 2026 - Late-stage and ABC-enabled therapies for neurodegeneration advance, with key data due 2024–2027.ALEC
Study Update8 Jul 2026 - Net loss narrowed to $22.9M as cost cuts and ABC platform advances extend cash runway through 2027.ALEC
Q1 20267 May 2026 - Board recommends approval of all proposals, emphasizing governance, risk, and ESG.ALEC
Proxy filing28 Apr 2026 - ABC platform delivers potent, safe brain-targeted therapies with strong clinical and market potential.ALEC
Corporate presentation26 Mar 2026 - Biotech firm seeks to raise up to $400M for neurodegenerative R&D via flexible securities offering.ALEC
Registration Filing12 Mar 2026